RJA
ALLO icon

Raymond James & Associates’s Allogene Therapeutics ALLO Stock Holding History

Raymond James & Associates’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-35,138
Closed -$379K – 3917
2022
Q3 		$379K Buy
+35,138
New +$477K ﹤0.01% 3030
2021
Q1 		– Sell
-15,495
Closed -$391K – 3993
2020
Q4 		$391K Buy
15,495
+8,939
+136% +$291K ﹤0.01% 2972
2020
Q3 		$247K Buy
6,556
+580
+10% +$21.9K ﹤0.01% 3069
2020
Q2 		$256K Buy
+5,976
New +$216K ﹤0.01% 3006
2019
Q2 		– Sell
-42,000
Closed -$1.21M – 3628
2019
Q1 		$1.21M Buy
42,000
+17,000
+68% +$493K ﹤0.01% 2077
2018
Q4 		$673K Buy
+25,000
New +$664K ﹤0.01% 2336

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raymond James & Associates's ALLO Position: Q4 2022 in Review

Raymond James & Associates sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 35,138 shares — an estimated $379K sold.

Raymond James & Associates first reported a position in ALLO in Q4 2018 and held it in 6 quarters. The position peaked at $1.21M in Q1 2019. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Raymond James & Associates reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 35,138 Allogene Therapeutics shares in Q4 2022, an estimated $379K.
  • Raymond James & Associates first reported a position in Allogene Therapeutics in Q4 2018 and held it in 6 quarters.
  • Raymond James & Associates's Allogene Therapeutics position peaked at $1.21M in Q1 2019.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.